作者
Giovanni Tommaso Ranaldi, Emanuele Rocco Villani, Laura Franza
发表日期
2020/7/1
来源
Medical gas research
卷号
10
期号
3
页码范围
134-138
出版商
Medknow
简介
Coronavirus disease 2019 (COVID-19) is the respiratory disease caused by the novel severe acute respiratory syndrome-coronavirus-2 and is characterized by clinical manifestations ranging from mild, flu-like symptoms to severe respiratory insufficiency and multi-organ failure. Patients with more severe symptoms may require intensive care treatments and face a high mortality risk. Also, thrombotic complications such as pulmonary embolisms and disseminated intravascular coagulation are frequent in these patients. Indeed, COVID-19 is characterized by an abnormal inflammatory response resembling a cytokine storm, which is associated to endothelial dysfunction and microvascular complications. To date, no specific treatments are available for COVID-19 and its life-threatening complication. Immunomodulatory drugs, such as hydroxychloroquine and interleukin-6 inhibitors, as well as antithrombotic drugs such …
学术搜索中的文章
GT Ranaldi, ER Villani, L Franza - Medical gas research, 2020